Literature DB >> 8366095

Myocyte-specific enhancer-binding factor (MEF-2) regulates alpha-cardiac myosin heavy chain gene expression in vitro and in vivo.

J D Molkentin1, B E Markham.   

Abstract

A myocyte-specific enhancer-binding factor (MEF-2) DNA binding site was identified in the rat alpha-myosin heavy chain (MHC) gene adjacent to the E-box binding site for alpha-MHC binding factor-2 (BF-2). Mutation of the MEF-2 site, within the context of the full-length promoter, reduced activity by 85 and 80% in neonatal cardiomyocytes and the adult heart, respectively. Mutation of the BF-2 site reduced activity approximately 70% in both models. A MEF-2/BF-2 double mutant gave significantly less activity than the BF-2 mutant but not the MEF-2 mutant, suggesting the possibility that BF-2 and MEF-2 interact. Mutations in MEF-2, which decreased functional activity, also abolished MEF-2 DNA binding activity. MEF-2 DNA binding activity was present in the developing heart, reached a peak in the late fetal and early neonatal stages, and then declined to low levels in the adult heart. The adult levels were sufficient to support alpha-MHC gene expression. MEF-2 activity was increased 2-3-fold in the adult heart subjected to a pressure or volume overload. Two working models are proposed as possible explanations of the antithetic relationship between MEF-2 levels and alpha-MHC gene expression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8366095

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Myocardial molecular biology: an introduction.

Authors:  Nigel J Brand; Paul J R Barton
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

2.  A conserved GATA motif in a tissue-specific DNase I hypersensitive site of the cardiac alpha-myosin heavy chain gene.

Authors:  W Y Huang; C C Liew
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

Review 3.  Re-employment of developmental transcription factors in adult heart disease.

Authors:  Toru Oka; Jian Xu; Jeffery D Molkentin
Journal:  Semin Cell Dev Biol       Date:  2006-11-24       Impact factor: 7.727

4.  Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload.

Authors:  T C Herzig; S M Jobe; H Aoki; J D Molkentin; A W Cowley; S Izumo; B E Markham
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

Review 5.  Kruppel-like Factors (KLFs) in muscle biology.

Authors:  Saptarsi M Haldar; Osama A Ibrahim; Mukesh K Jain
Journal:  J Mol Cell Cardiol       Date:  2007-04-19       Impact factor: 5.000

6.  Physical interaction between TBX5 and MEF2C is required for early heart development.

Authors:  Tushar K Ghosh; Fei Fei Song; Elizabeth A Packham; Sarah Buxton; Thelma E Robinson; Jonathan Ronksley; Tim Self; Andrew J Bonser; J David Brook
Journal:  Mol Cell Biol       Date:  2009-02-09       Impact factor: 4.272

7.  A positive GATA element and a negative vitamin D receptor-like element control atrial chamber-specific expression of a slow myosin heavy-chain gene during cardiac morphogenesis.

Authors:  G F Wang; W Nikovits; M Schleinitz; F E Stockdale
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

Review 8.  Genetic and epigenetic regulation of cardiomyocytes in development, regeneration and disease.

Authors:  Miao Cui; Zhaoning Wang; Rhonda Bassel-Duby; Eric N Olson
Journal:  Development       Date:  2018-12-20       Impact factor: 6.868

9.  Mutational analysis of the DNA binding, dimerization, and transcriptional activation domains of MEF2C.

Authors:  J D Molkentin; B L Black; J F Martin; E N Olson
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

10.  MEF2C silencing attenuates load-induced left ventricular hypertrophy by modulating mTOR/S6K pathway in mice.

Authors:  Ana Helena M Pereira; Carolina F M Z Clemente; Alisson C Cardoso; Thais H Theizen; Silvana A Rocco; Carla C Judice; Maria Carolina Guido; Vinícius D B Pascoal; Iscia Lopes-Cendes; José Roberto M Souza; Kleber G Franchini
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.